Due to manufacturing issues, Novartis has voluntarily suspended production of two therapies that use nuclear medicine to target and treat cancer cells, and also halted clinical trials for one of the treatments, which was approved in the U.S. only two months ago.
The company hit the pause button on Lutathera, which is used to treat neuroendocrine tumors and has been available since 2018. The other medication is Pluvicto, a prostate cancer drug that was recently endorsed by the U.S. Food and Drug Administration for treating a form of advanced cancer, although Novartis has high hopes it can eventually be used for combating earlier stages of the disease.
Create a display name to comment
This name will appear with your comment